Lung disease models

Expert solutions for pulmonary research

According to the World Health Organization (WHO), lung diseases are the second leading cause of death worldwide, and their significance is expected to increase over the next 20 years. Our company provides clinically relevant in vivo and ex vivo lung disease models, including pulmonary fibrosis and asthma. Our expert scientists utilise their expertise to design and conduct studies tailored specifically to the needs of our clients, supporting respiratory discovery programs effectively.

Lung fibrosis in vivo: clinically relevant models for drug discovery

Our lung fibrosis in vivo models offer a comprehensive approach to studying pulmonary fibrosis, a chronic and progressive lung disease. Using bleomycin-induced models, we simulate human lung fibrosis to assess the potency and anti-fibrotic efficacy of candidate compounds through clinically relevant pulmonary function parameters and histopathology readouts. Test compounds can be administered via various routes, including oral, subcutaneous and intranasal, with Nintedanib used as a standard-of-care reference for comparative analysis.

Lung fibrosis ex vivo: precision cut pulmonary slice (PCPS) models

Our lung fibrosis ex vivo models utilise precision cut pulmonary slices (PCPS), three-dimensional tissue explants derived from human or animal lungs. These models preserve the anatomical architecture and specific features of lung tissue, enabling comparative testing across various experimental conditions. PCPS models closely mimic in vivo conditions, making them invaluable for toxicological and pharmaceutical research, and serving as an effective alternative to traditional animal models in compound screening.

Image of Precision Cut Pulmonary Slices (PCPS) model

Asthma in vivo: preclinical models for drug discovery

Our asthma in vivo models offer a comprehensive approach to studying this complex and heterogeneous chronic inflammatory disease. We provide two distinct mouse models of house dust mite (HDM)-induced asthma, representing either eosinophilic or mixed-granulocytic asthma. These models enable the profiling of anti-inflammatory candidate compounds against standard-of-care treatments, with administration options including oral, subcutaneous and intranasal routes.

Image of eosinophilic HDM-induced asthma model

Contact us

Nuvisan is committed to protecting your privacy, and we'll only use your personal information to administer your account and to provide the products and services you requested from us. If you consent to us contacting you for this purpose, please tick below to say how you would like us to contact you:

I agree to receive other communications from Nuvisan. In order to provide you the content requested, we need to store and process your personal data. If you consent to us storing your personal data for this purpose, please tick the checkbox below.

I have read and agree to Nuvisan's privacy policy. I consent to the processing of my personal data for the provision of content by Nuvisan only. I understand that I can revoke this consent at any time and exercise my rights as detailed in the Privacy Policy.*

You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.

Email us

hello@nuvisan.com

Talk to us

+49 731 9840 0

Our locations

Neu-Ulm (headquarters)

Wegenerstrasse 13

89231 Neu-Ulm

Germany

Berlin

Muellerstrasse 178

13353 Berlin

Germany

Sophia Antipolis

2400 route des Colles

06410 Biot

France

Grafing

Am Feld 32

85567 Grafing

Germany

Waltrop

Im Wirrigen 25

45731 Waltrop

Germany

For concerns about pharmaceuticals or adverse drug-related events, contact us at: complaints@nuvisan.com